Search by Drug Name or NDC
NDC 00517-2051-25 Potassium Phosphates 236; 224 mg/mL; mg/mL Details
Potassium Phosphates 236; 224 mg/mL; mg/mL
Potassium Phosphates is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by American Regent, Inc.. The primary component is POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC.
Product Information
| NDC | 00517-2051 |
|---|---|
| Product ID | 0517-2051_90a23cc9-db2b-4f24-b2cf-ea7abf6c9944 |
| Associated GPIs | |
| GCN Sequence Number | 001285 |
| GCN Sequence Number Description | potassium phos,m-basic-d-basic VIAL 3MMOL/ML INTRAVEN |
| HIC3 | C1P |
| HIC3 Description | PHOSPHATE REPLACEMENT |
| GCN | 03591 |
| HICL Sequence Number | 000551 |
| HICL Sequence Number Description | POTASSIUM PHOSPHATE,MONOBASIC-DIBASIC |
| Brand/Generic | Generic |
| Proprietary Name | Potassium Phosphates |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | potassium phosphates |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 236; 224 |
| Active Ingredient Units | mg/mL; mg/mL |
| Substance Name | POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC |
| Labeler Name | American Regent, Inc. |
| Pharmaceutical Class | Increased Large Intestinal Motility [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Activity [MoA], |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA216274 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00517-2051-25 (00517205125)
| NDC Package Code | 0517-2051-25 |
|---|---|
| Billing NDC | 00517205125 |
| Package | 25 VIAL, SINGLE-DOSE in 1 TRAY (0517-2051-25) / 5 mL in 1 VIAL, SINGLE-DOSE (0517-2051-01) |
| Marketing Start Date | 2023-10-13 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |